Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10988485 | 0.87 | — | — | |
| SCHEMBL993593 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL1485343 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL856592 | 0.87 | — | — | |
| SCHEMBL127189 | 0.87 | — | — | |
| SCHEMBL127190 | 0.87 | — | — | |
| Phosphoric Acid SCHEMBL4422997 | 0.79 | NOS3 (0.44) | NOS2NOS3NOS1SLC7A5DDAH1 | |
| Trifluoroacetic Acid SCHEMBL1369861 | 0.78 | S1PR1 (0.36) | NOS2NOS1PTPN1GRB2S1PR1 | |
| Trifluoroacetic Acid SCHEMBL15821109 | 0.78 | S1PR1 (0.46) | S1PR1S1PR3S1PR2S1PR5 | |
| SCHEMBL9179525 | 0.76 | NOS3 (0.50) | NOS2NOS3NOS1SLC7A5DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133101-B2 | Processes for the preparation of (R)-2-acetamido-N-benzyl-3-methoxypropionamide and intermediates thereof | SIGNA S.A. DE C.V. (MX) | 2015-09-15 | — | — | US | disclosed |
| US-20150025274-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-ACETAMIDO-N-BENZYL-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | SIGNA S.A. DE C.V. (MX) | 2015-01-22 | — | — | US | disclosed |
| US-8759582-B2 | Process for the preparation of lacosamide | NATCO PHARMA LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-20130035508-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | NATCO PHARMA LIMITED (IN) | 2013-02-07 | — | — | US | disclosed |
| EP-2534128-A1 | A PROCESS FOR THE PREPARATION OF LACOSAMIDE | Natco Pharma Limited (IN) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011095995-A1 | A PROCESS FOR THE PREPARATION OF LACOSAMIDE | NATCO PHARMA LIMITED (IN) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035508-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | CA3, CACNA1A, CA2 | NOS2 3667/4885NOS3 3755/4885NOS1 4520/4885 |
| US-20150025274-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-ACETAMIDO-N-BENZYL-3-METHOXYPROPIONAMIDE AND INTERMEDIATES THEREOF | NAAA, CYP1A2, REN | NOS2 1444/4885NOS3 2071/4885NOS1 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.